Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
Department of Medicine, Sections of Hospital Medicine and of Infectious Diseases and Global Health, University of Chicago, Chicago, IL.
Mai T
MT
Pho
Benjamin P
BP
Linas
D016527:Drug Costs / Q000706:statistics & numerical data*; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic; D006575:Heterocyclic Compounds, 3-Ring / Q000191:economics*; D006801:Humans; D012254:Ribavirin / Q000191:economics*; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000191:economics*; D014542:Uridine Monophosphate / Q000031:analogs & derivatives* / Q000191:economics
D006575:Heterocyclic Compounds, 3-Ring; D013449:Sulfonamides; D012254:Ribavirin; D000069616:Simeprevir; D014542:Uridine Monophosphate; D000069474:Sofosbuvir